12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Company News  |  Deals

Seattle Genetics, Abbott, Astellas, Pfizer deal

Seattle Genetics disclosed in its 4Q11 earnings that it received undisclosed milestone payments from Abbott and Pfizer under separate 2011 deals granting the pharmas rights to use Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies to undisclosed cancer targets. The...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >